Dr. Secord on Treating Patients with Platinum Sensitive Ovarian Cancer

Video

Angeles A. Secord, MD, discusses treating patients with platinum-sensitive ovarian cancer.

Angeles A. Secord, MD, gynecologic oncologist, Duke Cancer Center, discusses treating patients with platinum-sensitive ovarian cancer.

Often, patients with platinum-sensitive ovarian cancer do not want to restart chemotherapy, so other therapeutic options are needed, Secord says. The integration of PARP inhibitors into the treatment paradigm has called a need to evaluate patients regarding what frontline treatments they received to determine if they are eligible for a PARP inhibitor, Secord says. 

Moreover, patients are evaluated in terms of their biomarkers, including whether they harbor BRCA1/2 mutations or if their tumor is characterized by homologous recombination deficiency or proficiency, also known as genomic instability, Secord explains.

Overall, if a patient has not received a PARP inhibitor in the frontline setting and they harbor BRCA1/2 mutations or genomic instability within their tumor, they should be considered for PARP inhibitor therapy. Additionally, the use of bevacizumab (Avastin) as a therapeutic option in the maintenance setting, as well as with concurrent chemotherapy, should also be discussed with the patient, Secord concludes.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,